Recent progress and related patents on the applications of bone marrow-derived stem/progenitor cells in regenerative medicine and cancer therapies

Murielle Mimeault, Surinder Kumar Batra

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recent progress and related patents in the field of bone marrow (BM)-resident adult stem/progenitor cell research have attracted well attention because these immature cells can act as the potential easily accessible cell sources for the cell transplantation in regenerative medicine and cancer therapies. The BM-resident hematopoietic stem/progenitor cells (HSCs and HPCs), mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs), endowed with a high self-renewal ability and multilineage differentiation potential, offer great promise to replace non-functional or lost cells and regenerate diseased and damaged tissues without a high-risk of graft rejection and major side effects. Particularly, the stimulation of the ex vivo or in vivo expansion and/or differentiation of a small subpopulation of BM-resident stem/progenitor cells or the use of genetically-modified BM stem/progenitor cells constitute potential cell-replacement and gene therapies with multiple applications in humans. Among the diseases that could be treated by the BM-derived stem/progenitor cell-based therapies, there are diverse hematopoietic, immune and vascular disorders, degenerative diseases such as Parkinson's and Alzheimer's diseases, diabetes mellitus as well as skin, liver, lung, and heart disorders. In addition, a combination of the current cancer therapies with an adjuvant treatment consisting of an autologous or allogeneic BM-derived stem/progenitor cell transplantation also represents a promising strategy for treating and even curing diverse aggressive, metastatic, recurrent and lethal cancers.

Original languageEnglish (US)
Pages (from-to)42-59
Number of pages18
JournalRecent Patents on Regenerative Medicine
Volume1
Issue number1
StatePublished - Jan 1 2011

Fingerprint

Regenerative Medicine
Patents
Stem Cells
Bone Marrow
Neoplasms
Therapeutics
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Stem Cell Research
Aptitude
Immune System Diseases
Cell Transplantation
Graft Rejection
Stem Cell Transplantation
Mesenchymal Stromal Cells
Bone Marrow Cells
Genetic Therapy
Blood Vessels
Parkinson Disease
Diabetes Mellitus

Keywords

  • Bone marrow
  • Endothelial progenitor cells
  • Gene therapy and cancer therapy
  • Hematopoiesis
  • Hematopoietic stem/progenitor cells
  • Mesenchymal stem cells
  • Regenerative medicine
  • Transplantation therapy

ASJC Scopus subject areas

  • Developmental Neuroscience
  • Developmental Biology
  • Cell Biology

Cite this

@article{e7504a25d0bd40f881f9912b33f8425f,
title = "Recent progress and related patents on the applications of bone marrow-derived stem/progenitor cells in regenerative medicine and cancer therapies",
abstract = "Recent progress and related patents in the field of bone marrow (BM)-resident adult stem/progenitor cell research have attracted well attention because these immature cells can act as the potential easily accessible cell sources for the cell transplantation in regenerative medicine and cancer therapies. The BM-resident hematopoietic stem/progenitor cells (HSCs and HPCs), mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs), endowed with a high self-renewal ability and multilineage differentiation potential, offer great promise to replace non-functional or lost cells and regenerate diseased and damaged tissues without a high-risk of graft rejection and major side effects. Particularly, the stimulation of the ex vivo or in vivo expansion and/or differentiation of a small subpopulation of BM-resident stem/progenitor cells or the use of genetically-modified BM stem/progenitor cells constitute potential cell-replacement and gene therapies with multiple applications in humans. Among the diseases that could be treated by the BM-derived stem/progenitor cell-based therapies, there are diverse hematopoietic, immune and vascular disorders, degenerative diseases such as Parkinson's and Alzheimer's diseases, diabetes mellitus as well as skin, liver, lung, and heart disorders. In addition, a combination of the current cancer therapies with an adjuvant treatment consisting of an autologous or allogeneic BM-derived stem/progenitor cell transplantation also represents a promising strategy for treating and even curing diverse aggressive, metastatic, recurrent and lethal cancers.",
keywords = "Bone marrow, Endothelial progenitor cells, Gene therapy and cancer therapy, Hematopoiesis, Hematopoietic stem/progenitor cells, Mesenchymal stem cells, Regenerative medicine, Transplantation therapy",
author = "Murielle Mimeault and Batra, {Surinder Kumar}",
year = "2011",
month = "1",
day = "1",
language = "English (US)",
volume = "1",
pages = "42--59",
journal = "Current Regenerative Medicine",
issn = "2468-4244",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Recent progress and related patents on the applications of bone marrow-derived stem/progenitor cells in regenerative medicine and cancer therapies

AU - Mimeault, Murielle

AU - Batra, Surinder Kumar

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Recent progress and related patents in the field of bone marrow (BM)-resident adult stem/progenitor cell research have attracted well attention because these immature cells can act as the potential easily accessible cell sources for the cell transplantation in regenerative medicine and cancer therapies. The BM-resident hematopoietic stem/progenitor cells (HSCs and HPCs), mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs), endowed with a high self-renewal ability and multilineage differentiation potential, offer great promise to replace non-functional or lost cells and regenerate diseased and damaged tissues without a high-risk of graft rejection and major side effects. Particularly, the stimulation of the ex vivo or in vivo expansion and/or differentiation of a small subpopulation of BM-resident stem/progenitor cells or the use of genetically-modified BM stem/progenitor cells constitute potential cell-replacement and gene therapies with multiple applications in humans. Among the diseases that could be treated by the BM-derived stem/progenitor cell-based therapies, there are diverse hematopoietic, immune and vascular disorders, degenerative diseases such as Parkinson's and Alzheimer's diseases, diabetes mellitus as well as skin, liver, lung, and heart disorders. In addition, a combination of the current cancer therapies with an adjuvant treatment consisting of an autologous or allogeneic BM-derived stem/progenitor cell transplantation also represents a promising strategy for treating and even curing diverse aggressive, metastatic, recurrent and lethal cancers.

AB - Recent progress and related patents in the field of bone marrow (BM)-resident adult stem/progenitor cell research have attracted well attention because these immature cells can act as the potential easily accessible cell sources for the cell transplantation in regenerative medicine and cancer therapies. The BM-resident hematopoietic stem/progenitor cells (HSCs and HPCs), mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs), endowed with a high self-renewal ability and multilineage differentiation potential, offer great promise to replace non-functional or lost cells and regenerate diseased and damaged tissues without a high-risk of graft rejection and major side effects. Particularly, the stimulation of the ex vivo or in vivo expansion and/or differentiation of a small subpopulation of BM-resident stem/progenitor cells or the use of genetically-modified BM stem/progenitor cells constitute potential cell-replacement and gene therapies with multiple applications in humans. Among the diseases that could be treated by the BM-derived stem/progenitor cell-based therapies, there are diverse hematopoietic, immune and vascular disorders, degenerative diseases such as Parkinson's and Alzheimer's diseases, diabetes mellitus as well as skin, liver, lung, and heart disorders. In addition, a combination of the current cancer therapies with an adjuvant treatment consisting of an autologous or allogeneic BM-derived stem/progenitor cell transplantation also represents a promising strategy for treating and even curing diverse aggressive, metastatic, recurrent and lethal cancers.

KW - Bone marrow

KW - Endothelial progenitor cells

KW - Gene therapy and cancer therapy

KW - Hematopoiesis

KW - Hematopoietic stem/progenitor cells

KW - Mesenchymal stem cells

KW - Regenerative medicine

KW - Transplantation therapy

UR - http://www.scopus.com/inward/record.url?scp=84876511943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876511943&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 42

EP - 59

JO - Current Regenerative Medicine

JF - Current Regenerative Medicine

SN - 2468-4244

IS - 1

ER -